SLC2A3 and glioblastoma: Interestingly, in contrast with GLUT1, GLUT3 expression is primarily elevated in GSCs and its expression highly correlates with poor survival in GBM [19], suggesting that targeting GLUT3 would more specifically disrupt GSCs.